The MGMT promoter has been an important target in both newly diagnosed glioblastoma and recurrent glioblastoma as the protein product, AGT, yields resistance to alkylating chemotherapy such as TMZ [51,89]. This evidence concerns the gene MGMT and glioblastoma.